4.7 Article

Mitochondrial-Mediated Apoptosis in Lymphoma Cells by the Diterpenoid Lactone Andrographolide, the Active Component of Andrographis paniculata

期刊

CLINICAL CANCER RESEARCH
卷 16, 期 19, 页码 4755-4768

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-10-0883

关键词

-

类别

资金

  1. National Cancer Institute [K23 CA109613-A1]

向作者/读者索取更多资源

Purpose: Andrographolide is a diterpenoid lactone isolated from Andrographis paniculata (King of Bitters), an herbal medicine used in Asia. It has been reported to have anti-inflammatory, antihypertensive, antiviral, and immune-stimulant properties. Furthermore, it has been shown to inhibit cancer cell proliferation and induce apoptosis in leukemia and solid tumor cell lines. Experimental Design: We studied the Burkitt p53-mutated Ramos cell line, the mantle cell lymphoma (MCL) line Granta, the follicular lymphoma (FL) cell line HF-1, and the diffuse large B-cell lymphoma (DLBCL) cell line SUDHL4, as well as primary cells from patients with FL, DLBCL, and MCL. Results: We found that andrographolide resulted in dose-and time-dependent cell death as measured by MTT. Andrographolide significantly increased reactive oxygen species (ROS) production in all cell lines. To determine mechanism of cell death, we measured apoptosis by Annexin V/propidium iodide in the presence and absence of the antioxidant N-acetyl-L-cysteine (NAC), the glutathione (GSH)-depleting agent buthionine sulfoxamine (BSO), or caspase inhibitors. We found that apoptosis was greatly enhanced by BSO, blocked by NAC, and accompanied by poly(ADP-ribose) polymerase cleavage and activation of caspase-3, caspase-8, and caspase-9. We measured BAX conformational change and mitochondrial membrane potential, and using mouse embryonic fibroblast (MEF) Bax/Bak double knockouts (MEFBax-/-/Bak-/-), we found that apoptosis was mediated through mitochondrial pathways, but dependent on caspases in both cell lines and patient samples. Conclusions: Andrographolide caused ROS-dependent apoptosis in lymphoma cell lines and in primary tumor samples, which was enhanced by depletion of GSH and inhibited by NAC or the pan-caspase inhibitor Z-VAD-FMK. Further studies of diterpenoid lactones in lymphoma are warranted. Clin Cancer Res; 16(19); 4755-68. (C) 2010 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Oncology

Current Treatment Options for Older Patients with Hodgkin Lymphoma

Jordan Carter, Kevin A. David, Athena Kritharis, Andrew M. Evens

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2020)

Article Hematology

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Pamela B. Allen, Hatice Savas, Andrew M. Evens, Ranjana H. Advani, Brett Palmer, Barbara Pro, Reem Karmali, Eric Mou, Jeffrey Bearden, Gary Dillehay, Robert A. Bayer, Robert M. Eisner, Joan S. Chmiel, Kaitlyn O'Shea, Leo I. Gordon, Jane N. Winter

Summary: Brief pembrolizumab monotherapy followed by AVD is highly effective and safe for patients with newly diagnosed classical Hodgkin lymphoma, including those with bulky disease.
Article Oncology

SARS-CoV-2 nosocomial infection: Real-world results of environmental surface testing from a large tertiary cancer center

Mansi R. Shah, Imraan Jan, Jeremy Johns, Kuldip Singh, Pallavi Kumar, Norma Belarmino, Kara J. Saggiomo, Carolyn Hayes, Kimyatta Washington, Deborah L. Toppmeyer, Bruce G. Haffty, Steven K. Libutti, Andrew M. Evens

Summary: Strict adherence to infection control protocols in outpatient and inpatient oncology units results in minimal environmental contamination with SARS-CoV-2.

CANCER (2021)

Article Oncology

Burkitt Lymphoma International Prognostic Index

Adam J. Olszewski, Lasse H. Jakobsen, Graham P. Collins, Kate Cwynarski, Veronika Bachanova, Kristie A. Blum, Kirsten M. Boughan, Mark Bower, Alessia Dalla Pria, Alexey Danilov, Kevin A. David, Catherine Diefenbach, Fredrik Ellin, Narendranath Epperla, Umar Farooq, Tatyana A. Feldman, Alina S. Gerrie, Deepa Jagadeesh, Manali Kamdar, Reem Karmali, Shireen Kassam, Vaishalee P. Kenkre, Nadia Khan, Seo-Hyun Kim, Andreas K. Klein, Izidore S. Lossos, Matthew A. Lunning, Peter Martin, Nicolas Martinez-Calle, Silvia Montoto, Seema Naik, Neil Palmisiano, David Peace, Elizabeth H. Phillips, Tycel J. Phillips, Craig A. Portell, Nishitha Reddy, Anna Santarsieri, Maryam Sarraf Yazdy, Knut B. Smeland, Scott E. Smith, Stephen D. Smith, Suchitra Sundaram, Adam S. Zayac, Xiao-Yin Zhang, Catherine Zhu, Chan Y. Cheah, Tarec C. El-Galaly, Andrew M. Evens

Summary: The BL-IPI provides robust discrimination of survival in adult BL, suitable for use as prognostication and stratification in trials. The high-risk group has suboptimal outcomes with standard therapy and should be considered for innovative treatment approaches.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Review Hematology

Defining and treating high-grade B-cell lymphoma, NOS

Adam J. Olszewski, Habibe Kurt, Andrew M. Evens

Summary: High-grade B-cell lymphoma, not otherwise specified (HGBL, NOS) is a recently introduced diagnostic category for aggressive B-cell lymphomas. It includes rare and heterogeneous tumors that cannot be classified as other well-defined lymphoma subtypes. Improved molecular diagnostics are needed to improve outcomes and treatment for patients.
Article Oncology

Survivorship transition care experiences and preparedness for survivorship among a diverse population of cancer survivors in New Jersey

Angela J. Fong, Andrew M. Evens, Elisa Bandera, Adana A. M. Llanos, Katie A. Devine, Shawna Hudson, Bo Qin, Lisa E. Paddock, Antoinette M. Stroup, Sara Frederick, Carissa Greco, Sharon L. Manne

Summary: This study aimed to characterize the preparedness for survivorship and evaluate the factors associated with it, including sociodemographic, medical, survivorship care transition experiences, practical and psychological factors. The findings revealed that many cancer survivors felt unprepared for survivorship and desired more information about follow-up tests and maintaining good health. Factors such as receiving chemotherapy, limited transition care planning, limited discussion of medical and psychosocial effects, high information needs, and financial hardship predicted low preparedness.

EUROPEAN JOURNAL OF CANCER CARE (2022)

Article Hematology

Checkpoint inhibitor immunotherapy during pregnancy for relapsed-refractory Hodgkin lymphoma

Andrew M. Evens, Justin S. Brandt, Cody J. Peer, Tyler Yin, Dale Schaar, Faheem Farooq, Brett Mozarsky, William D. Figg, Elad Sharon

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Review Oncology

Treatment Strategies for Advanced Classical Hodgkin Lymphoma in the Times of Dacarbazine Shortage

Pallawi Torka, Eugene Przespolewski, Andrew M. Evens

Summary: The shortage of dacarbazine (DTIC) has caused a crisis in treating classical Hodgkin lymphoma. This review discusses strategies and proposes a treatment algorithm based on fitness and safety for receiving anthracyclines.

JCO ONCOLOGY PRACTICE (2022)

Editorial Material Oncology

Drug Shortages and Curative Cancer Therapy: The Problem of Dacarbazine and Classical Hodgkin's Lymphoma

Nicole Soriano, Kate Berlin, Leo I. Gordon

JCO ONCOLOGY PRACTICE (2022)

Article Hematology

Enhanced systemic antilymphoma immune response by photothermal therapy with CpG deoxynucleotide-coated nanoparticles

Adam Yuh Lin, Bongseo Choi, Taehoon Sim, Eva Yang, Hyunjun Choi, Amir Behdad, Dong-Hyun Kim, Leo I. Gordon

Summary: This study investigates a novel mechanism of in situ vaccination in lymphoma. By combining cytosine guanine dinucleotide (CpG) deoxynucleotides with radiation therapy (RT) or photothermal therapy (PTT), an enhanced abscopal response and immune stimulation could be achieved. The results show that the combination of CpG deoxynucleotides with PTT significantly reduces tumor growth and increases CD8/CD4 and cytotoxic T-cell/regulatory T-cell ratios in the tumor microenvironment, as well as promoting effector memory T cells in lymph nodes and spleen.

BLOOD ADVANCES (2022)

Editorial Material Oncology

The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma

Reem Karmali, Frederique St-Pierre, Leo Gordon

FUTURE ONCOLOGY (2023)

Article Hematology

Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma

Jia Ruan, Jasmine Zain, Brett Palmer, Borko Jovanovic, Xinlei Mi, Alok Swaroop, Jane N. Winter, Leo I. Gordon, Reem Karmali, Jonathan Moreira, Adam M. Petrich, Barbara Pro

Summary: This study evaluated the combination of romidepsin and lenalidomide as initial treatment for PTCL and found that it is feasible and effective, showing promising overall response rates and survival outcomes.

BLOOD ADVANCES (2023)

Article Oncology

Observations of Oncologists on Treatment Selection With Interim Positron Emission Tomography-Adapted Approaches in Classic Hodgkin Lymphoma: The Real-World CONNECT Study

Susan K. Parsons, Kristina S. Yu, Nicholas Liu, Supriya Kumar, Michelle A. Fanale, Katie Holmes, Carlos Flores, Andy Surinach, Darcy R. Flora, Andrew M. Evens

Summary: This study surveyed oncologists treating cHL to understand the treatment decision process, including the impact of PET/CT imaging.

JCO ONCOLOGY PRACTICE (2023)

Article Oncology

Physician frontline treatment preferences for stage III/IV classic Hodgkin lymphoma: the real-world US CONNECT study

Andrew M. Evens, Kristina S. Yu, Nicholas Liu, Andy Surinach, Katherine Holmes, Carlos Flores, Michelle A. Fanale, Darcy R. Flora, Susan K. Parsons

Summary: This study aimed to understand the treatment preferences and decision-making of US physicians when it comes to frontline treatment for stage III/IV classic Hodgkin lymphoma (cHL). Results showed that the most common factors considered by physicians when selecting 1L cHL treatments were trial efficacy/safety data and national guidelines. Although treatment selection varied based on patient characteristics, overall survival (OS) was consistently cited as the most important attribute.

FUTURE ONCOLOGY (2023)

Article Hematology

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Andrew M. Evens, Alexey Danilov, Deepa Jagadeesh, Amy Sperling, Seo-Hyun Kim, Ryan Vaca, Catherine Wei, Daniel Rector, Suchitra Sundaram, Nishitha Reddy, Yong Lin, Umar Farooq, Christopher D'Angelo, David A. Bond, Stephanie Berg, Michael C. Churnetski, Amandeep Godara, Nadia Khan, Yun Kyong Choi, Maryam Yazdy, Emma Rabinovich, Gaurav Varma, Reem Karmali, Agrima Mian, Malvi Savani, Madelyn Burkart, Peter Martin, Albert Ren, Ayushi Chauhan, Catherine Diefenbach, Allandria Straker-Edwards, Andreas K. Klein, Kristie A. Blum, Kirsten Marie Boughan, Scott E. Smith, Brad M. Haverkos, Victor M. Orellana-Noia, Vaishalee P. Kenkre, Adam Zayac, Jeremy Ramdial, Seth M. Maliske, Narendranath Epperla, Parameswaran Venugopal, Tatyana A. Feldman, Stephen D. Smith, Andrzej Stadnik, Kevin A. David, Seema Naik, Izidore S. Lossos, Matthew A. Lunning, Paolo Caimi, Manali Kamdar, Neil Palmisiano, Veronika Bachanova, Craig A. Portell, Tycel Phillips, Adam J. Olszewski, Juan Pablo Alderuccio

Summary: The study found that patients with Burkitt lymphoma who received rituximab treatment had higher survival rates, while factors such as age, ECOG performance status, lactate dehydrogenase levels, and central nervous system involvement could affect patient survival.
暂无数据